130 related articles for article (PubMed ID: 8032960)
1. Phase II evaluation of amonafide in advanced sarcoma: a Southwest Oncology Group study.
Buys SS; Metch B; Balcerzak SP; Neefe JR; Stuckey WJ
Cancer Invest; 1994; 12(4):399-402. PubMed ID: 8032960
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of amonafide in advanced and recurrent sarcoma patients.
Perez RP; Nash SL; Ozols RF; Comis RL; O'Dwyer PJ
Invest New Drugs; 1992 Jul; 10(2):99-101. PubMed ID: 1500272
[TBL] [Abstract][Full Text] [Related]
3. Amonafide as first-line chemotherapy for metastatic breast cancer.
Kornek G; Raderer M; Depisch D; Haider K; Fazeny B; Dittrich C; Scheithauer W
Eur J Cancer; 1994; 30A(3):398-400. PubMed ID: 8204367
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of amonafide in advanced pancreas cancer. A Southwest Oncology Group study.
Leichman CG; Tangen C; Macdonald JS; Leimert T; Fleming TR
Invest New Drugs; 1993; 11(2-3):219-21. PubMed ID: 8262735
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of amonafide in patients with advanced metastatic or recurrent endometrial adenocarcinoma. A Southwest Oncology Group study.
Malviya VK; Liu PY; O'Toole R; Alberts DS; Surwit E; Rosenoff S; Ward JH; Yu A; O'Sullivan J; Craig JB
Am J Clin Oncol; 1994 Feb; 17(1):37-40. PubMed ID: 8311005
[TBL] [Abstract][Full Text] [Related]
6. A phase II trial of amonafide in patients with endometrial cancer: a Gynecologic Oncology Group Study.
Asbury R; Blessing JA; Reid GC; McGuire WP
Am J Clin Oncol; 1998 Aug; 21(4):406-7. PubMed ID: 9708643
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of amonafide in disseminated malignant melanoma. A Southwest Oncology Group study.
Slavik M; Kopecky KJ; Sondak V; Craig JB; Samson MK
Invest New Drugs; 1993; 11(2-3):223-6. PubMed ID: 8262736
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of amonafide for the treatment of advanced, hormonally refractory carcinoma of the prostate. A Southwest Oncology Group study.
Marshall ME; Blumenstein B; Crawford ED; Thompson IM; Craig JB; Eisenberger M; Ahmann F
Am J Clin Oncol; 1994 Dec; 17(6):514-5. PubMed ID: 7977172
[TBL] [Abstract][Full Text] [Related]
9. Amonafide in patients with leiomyosarcoma of the uterus: a phase II Gynecologic Oncology Group study.
Asbury R; Blessing JA; Buller R; Malfetano JH; Walker J; Sevin BU
Am J Clin Oncol; 1998 Apr; 21(2):145-6. PubMed ID: 9537200
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of amonafide in advanced pancreatic adenocarcinoma.
Linke K; Pazdur R; Abbruzzese JL; Ajani JA; Winn R; Bradof JE; Daugherty K; Levin B
Invest New Drugs; 1991 Nov; 9(4):353-6. PubMed ID: 1804812
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of amonafide (nafidamide, NSC 308847) in advanced colorectal cancer.
O'Dwyer PJ; Paul AR; Hudes GR; Walczak J; Ozols RF; Comis RL
Invest New Drugs; 1991 Feb; 9(1):65-7. PubMed ID: 2026485
[TBL] [Abstract][Full Text] [Related]
12. A phase II trial of amonafide in patients with mixed mesodermal tumors of the uterus: a Gynecologic Oncology Group study.
Asbury R; Blessing JA; Podczaski E; Ball H
Am J Clin Oncol; 1998 Jun; 21(3):306-7. PubMed ID: 9626805
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of amonafide in advanced breast cancer.
Scheithauer W; Dittrich C; Kornek G; Haider K; Linkesch W; Gisslinger H; Depisch D
Breast Cancer Res Treat; 1991 Dec; 20(1):63-7. PubMed ID: 1813070
[TBL] [Abstract][Full Text] [Related]
14. Amonafide: An active agent in the treatment of previously untreated advanced breast cancer--a cancer and leukemia group B study (CALGB 8642).
Costanza ME; Berry D; Henderson IC; Ratain MJ; Wu K; Shapiro C; Duggan D; Kalra J; Berkowitz I; Lyss AP
Clin Cancer Res; 1995 Jul; 1(7):699-704. PubMed ID: 9816035
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of amonafide in advanced colorectal cancer: a SouthWest Oncology Group study.
Brown TD; Goodman PJ; Fleming T; Macdonald JS; Craig JB; Einstein AB
Anticancer Drugs; 1993 Feb; 4(1):49-50. PubMed ID: 8457714
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of amonafide in the treatment of patients with advanced squamous cell carcinoma of the head and the neck. An Illinois Cancer Center study.
Rosen F; Vokes EE; Lad T; Kies M; Wade J; Kilton LJ; Blough R; French S; Mullane M; Benson AB
Invest New Drugs; 1995; 13(3):249-52. PubMed ID: 8729954
[TBL] [Abstract][Full Text] [Related]
17. A randomized phase II trial of amonafide or trimetrexate in patients with advanced non-small cell lung cancer. A trial of the North Central Cancer Treatment Group.
Gesme DH; Jett JR; Schreffler DD; Su JQ; Mailliard JA; Foley JF; Krook JE; Maksymiuk AW; Hatfield AK; Ebbert LP
Cancer; 1993 May; 71(9):2723-6. PubMed ID: 8385564
[TBL] [Abstract][Full Text] [Related]
18. Phase I clinical investigation of amonafide.
Saez R; Craig JB; Kuhn JG; Weiss GR; Koeller J; Phillips J; Havlin K; Harman G; Hardy J; Melink TJ
J Clin Oncol; 1989 Sep; 7(9):1351-8. PubMed ID: 2549205
[TBL] [Abstract][Full Text] [Related]
19. An ECOG phase II study of amonafide in unresectable or recurrent carcinoma of the head and neck (PB390). Eastern Cooperative Oncology Group.
Leaf AN; Neuberg D; Schwartz EL; Wadler S; Ritch PS; Dutcher JP; Adams GL
Invest New Drugs; 1997; 15(2):165-72. PubMed ID: 9220297
[TBL] [Abstract][Full Text] [Related]
20. A Gynecologic Oncology Group phase II study of amonafide (NSC #308847) in squamous cell carcinoma of the cervix.
Asbury RF; Blessing JA; Soper JT
Am J Clin Oncol; 1994 Apr; 17(2):125-8. PubMed ID: 8141104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
